Business Wire

THALES

30.11.2022 16:01:47 CET | Business Wire | Press release

Share
Thales Collaborates with AWS to Support Digital Sovereignty for Cloud Customers via CipherTrust Cloud Key Manager Integration

Thales today announced the launch of its CipherTrust Cloud Key Manager integration with the AWS External Key Store, a feature of the AWS Key Management Service announced at AWS re:Invent 2022. Following an increased call for enhanced sovereign controls amid growing regulatory requirements, the integration enables organisations to retain control of their encryption keys when migrating their sensitive data to the AWS cloud.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221130005542/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

Developed with Thales since its inception, the AWS External Key Store combined with CipherTrust Cloud Key Manager offers organisations looking to move critical workloads to the cloud a way to maintain sovereign control of sensitive data throughout their digital transformation journey.

“We’ve had a strong technical collaboration with Thales on the development of the AWS External Key Store specification from the very beginning, in part due to their long history of expertise developing hardware security modules and key management services,” said Ken Beer, General Manager, Key Management Service at AWS. “The cloud has become a critical point of operation across businesses, and our combined expertise provides a way of helping organisations address specific needs and know they’re getting industry-best security controls in the process.”

According to the Thales 2022 Cloud Security Study, encryption is the number one choice to protect data in the cloud. However, only about one-third (29%) of respondents report total control of their keys to encrypted data in the cloud. User-controlled encryption and key management in hybrid IT are essential safeguards to enforce digital sovereignty in a modern data-driven world governed by privacy compliance mandates, regulated sectors, or general IT security recommendations such as the Shared Responsibility Model and the NIS2 Directive.

CipherTrust Cloud Key Manager ensures AWS External Key Store customers can satisfy these urgent regulatory requirements by leveraging strong encryption and data security methods that allow organisations to manage their data separately from the cloud service provider. Such a safeguard, also known as Hold Your Own Key (HYOK), enables organisations to maintain key ownership separate from the cloud data store.

“Varying data protection regulations across countries have presented a challenge for global organisations migrating to the cloud,” said Heleen Herselman, VP AWS Powerhouse at T-Systems Cloud Service. “The CipherTrust Cloud Key Manager simplifies this challenge and ensures we remain compliant while taking advantage of all the benefits of leveraging cloud services. The ability to lean on Thales’ solution has become especially important, as we, and other organisations, increasingly rely on multi-cloud environments.”

CipherTrust Cloud Key Manager is an industry-leading multi-cloud encryption key life cycle management solution that supports all major public cloud service providers. With a marked increase in multi-cloud adoption, this solution allows users to centralise key management across all clouds.

“This is the first integration on the market to solve a major pain point for AWS cloud customers: how can they utilise protected data in the AWS cloud while retaining encryption keys outside the cloud.” said Todd Moore, VP, Encryption Products at Thales. “As an industry leader in key management solutions, we are proud to offer an encryption solution that provides the ability to maintain external control of keys and cryptographic operations using those keys. CipherTrust Cloud Key Manager is at the forefront of advanced digital sovereignty. We’ll continue to introduce cutting-edge security and compliance features that support organisations in their digital transformation journeys.”

The Thales CipherTrust Cloud Key Manager integration for AWS External Key Store is available today. For more information, visit our landing page.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.

Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.

PLEASE VISIT

Thales Group
Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221130005542/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye